Product Description
In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. ... Read more

Product Description
An up-to-date reference on this fascinating set of complex disorders, this book features the most comprehensive strategies for diagnosing, classifying, imaging, treating, and managing amyloidosis in multiple organ systems. Beneficial to the spectrum of practitioners from residents to sub-specialists, this book is a succinct authoritative text written by leaders in the field. The authors provide instruction on all forms of amyloidosis - including primary amyloidosis (AL), secondary amyloidosis (AA), and familial amyloidosis. With essential treatment algorithms, Amyloidosis: Diagnosis and Treatment is the gold-standard for all hematologists, oncologists, and internists caring for patients with this complex disease. ... Read more

Product Description
Dialysis-related amyloidosis is a freequent complication encountered in patients receiving long-term haemodialysis. This book presents evidence on the possible role of beta2-microglobulin modified with advanced glycation end products (AGE) in the pathogenesis of the disease. The first of the three sections investigates the structure of AGE-modified protein, its formation mechanisms and its biological activity. The book reveals that AGE-modified beta2-microglobulin has a chemotactic effect on monocytes, and stimulates macrophages to secrete interleuken 1beta, interleuken 6 and TNFalpha. In other sections, the factors causing dialysis related amyloidosis are examined and the effectiveness of various haemo-purification methods in alleviating osteoarthropathy are assessed. ... Read more

Product Description
This is a massive volume of 608 pages representing the most complete and up-to-date clinical and research reference available on amyloid and amyloidosis. The book contains 183 chapters, fully illustrated and referenced, in six sections covering fibril formation, AL amyloidosis, familial amyloidosis, AA amyloidosis, Alzheimer's and prion disease, and other forms of amyloidosis. The authors are world leaders in the field. Includes bibliographic references and index. Publication Note: This volume is the Proceedings of the VIIIth International Symposium on Amyloidosis, August 7-11, 1998, Rochester, Minnesota, USA. ... Read more

Product Description
Abstract: Primary systemic amyloidosis is a light-chain immunoglobulin disorder that causes nonlocalized or multisystem symptoms. Patients with cardiac involvement have a poor prognosis. Fortunately, many effective treatments have become available in recent years. Early diagnosis and institution of treatment is critical to improving survival rates and quality of life. In this article, the authors highlight common clinical presentations, suggest diagnostic workup techniques, and discuss treatment options, including autologous stem cell transplantation.

Amyloidosis is a rare disorder characterized by deposition of amorphous hyaline-appearing material in the intercellular space. Congo red staining of amyloid produces character-istic red-green birefringence under polarized light.1 At the ultrastructural level, amyloid protein consists of fibrillar, nonbranching material deposited in a distinct ƒÀ-pleated configuration.2

Amyloidosis is characterized by the type of protein deposited. The most common of several types of systemic amyloidosis, primary systemic amyloidosis (also called light-chain amyloidosis, or AL) is caused by deposition of monoclonal light chains or light-chain fragments as amyloid. These chains are derived from a monoclonal plasma cell population, although it may not always be evident. The incidence of primary systemic amyloidosis is estimated to be 1 in 100,000 adults in the United States. Like other plasma cell dyscrasias, primary systemic amyloidosis affects older adults (median age at presentation, 65 years).3 No risk factors or sex or racial predispositions have been described.

The incidence of primary systemic amyloidosis is similar to that of Hodgkin's disease, Myco-bacterium avium complex infection, and polycythemia vera. Therefore, primary care physicians can expect to see patients with primary systemic amyloidosis in their practice. However, primary care physicians are often not very familiar with amyloidosis. Patients frequently present with nonspecific or vague symptoms, and it may be several months before diagnosis is made. Early diagnosis and treatment are crucial to achieving a satisfactory outcome.

Here, we present an illustrative case followed by a review of clinical features and diag-nostic and management approaches. We also highlight recent advances in treatment of primary systemic amyloidosis. The availability of potentially life-prolonging treatments underscores the importance of timely diagnosis so that therapy can be instituted before the pa-tient's condition irreversibly deteriorates. ... Read more

Product Description
This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2003. The length of the article is 564 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Primary nodular amyloidosis seldom progresses. (Mayo Clinic Series).
Author: Bruce Jancin
Publication: Skin & Allergy News (Magazine/Journal)
Date: June 1, 2003
Publisher: International Medical News Group
Volume: 34Issue: 6Page: 37(1)

Distributed by Thomson Gale ... Read more

Product Description
This digital document is an article from Dermatology Nursing, published by Jannetti Publications, Inc. on June 1, 2004. The length of the article is 3924 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Managing the patient with amyloidosis.
Author: Jan D. Cannon
Publication: Dermatology Nursing (Refereed)
Date: June 1, 2004
Publisher: Jannetti Publications, Inc.
Volume: 16Issue: 3Page: 225(8)

Distributed by Thomson Gale ... Read more

Product Description
Part 1 Quantification of amyloid A (AA) protein in serum and fat tissue using a monoclonal ELISAPart 2 Iodine-labeled serum amyloid P component (SAP) ... Read more

Product Description
This digital document is an article from Southern Medical Journal, published by Southern Medical Association on May 1, 2003. The length of the article is 1719 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment. (Case Report).(medical research)
Author: Ramazan Cetinkaya
Publication: Southern Medical Journal (Refereed)
Date: May 1, 2003
Publisher: Southern Medical Association
Volume: 96Issue: 5Page: 491(3)

Distributed by Thomson Gale ... Read more